Education
About Us
Working with TipRanks
Follow Us
Coeptis Therapeutics Holdings (COEP)
NASDAQ:COEP
COEP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.31 - $14.70
Previous Close$6.8
Volume106.19K
Average Volume (3M)57.39K
Market Cap
$63.68M
Enterprise Value$0.00
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-0.09
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.65
Shares Outstanding4,820,317
10 Day Avg. Volume53,383
30 Day Avg. Volume57,391
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Coeptis Therapeutics Holdings News
COEP FAQ
What was Coeptis Therapeutics Holdings’s price range in the past 12 months?
Coeptis Therapeutics Holdings lowest stock price was $2.31 and its highest was $14.70 in the past 12 months.
What is Coeptis Therapeutics Holdings’s market cap?
Coeptis Therapeutics Holdings’s market cap is $63.68M.
When is Coeptis Therapeutics Holdings’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Coeptis Therapeutics Holdings’s earnings last quarter?
Currently, no data Available
Is Coeptis Therapeutics Holdings overvalued?
According to Wall Street analysts Coeptis Therapeutics Holdings’s price is currently Overvalued.
Does Coeptis Therapeutics Holdings pay dividends?
Coeptis Therapeutics Holdings does not currently pay dividends.
What is Coeptis Therapeutics Holdings’s EPS estimate?
Coeptis Therapeutics Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Coeptis Therapeutics Holdings have?
Coeptis Therapeutics Holdings has 4,820,317 shares outstanding.
What happened to Coeptis Therapeutics Holdings’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Coeptis Therapeutics Holdings?
Currently, no hedge funds are holding shares in COEP
Coeptis Therapeutics Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
231.50%
12-Months-Change
Fundamentals
Return on Equity
-171.56%
Trailing 12-Months
Asset Growth
4.84%
Trailing 12-Months
Company Description
Coeptis Therapeutics Holdings
Coeptis Therapeutics, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.
Coeptis Therapeutics Holdings (COEP) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
Technical Analysis
Akari Therapeutics
―
X4 Pharmaceuticals
―
NRX Pharmaceuticals
―
LAVA Therapeutics
―
Cadrenal Therapeutics, Inc.
―
Ownership Overview
3.03%
Insiders
3.11% Mutual Funds
― Other Institutional Investors
96.74% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---